OncoLens replaces the current labor intensive process of patient case collaboration and subsequent CoC accreditation in cancer care.
OncoLens has raised $16.0M in total funding. The most recent round was Series B. The last funding was announced in October 2024.
OncoLens's investors include SeedToB Capital, BIP Capital, Cross-Border Impact Ventures, Martin Ventures, Atlanta Technology Angels.
OncoLens is headquartered in Atlanta, United States.
OncoLens replaces the current labor intensive process of patient case collaboration and subsequent CoC accreditation in cancer care.
OncoLens is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"OncoLens — Funding & Investors." VCBacked, October 24, 2024, https://www.vcbacked.co/company/oncolens. Accessed September 13, 2026.
VCBacked. (2024). OncoLens — Funding & Investors. Retrieved September 13, 2026, from https://www.vcbacked.co/company/oncolens
{{cite web |title=OncoLens — Funding & Investors |url=https://www.vcbacked.co/company/oncolens |website=VCBacked |access-date=September 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated